Travere to Submit sNDA for FILSPARI® (sparsentan) in FSGS Kidney Disorder

 Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25

If approved, FILSPARI could be the first and only approved medicine indicated for FSGS, a rare kidney disorder and leading cause of kidney failure

sNDA submission to be based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS

Company to host conference call and webcast today at 8:30 a.m. ET

Travere Therapeutics will host a conference call and webcast to discuss these updates today, Tuesday, February 11, 2025, at 8:30 a.m. ET. To participate in the conference call, dial +1 (800) 549-8228 (U.S.) or +1 (646) 564-2877 (International), conference ID 05607.

The webcast can be accessed on the Investor page of Travere’s website at ir.travere.com/events-presentations. Following a live webcast, archived version of the call will be available for 30 days on the Company’s website.

https://www.globenewswire.com/news-release/2025/02/11/3024045/0/en/Travere-Therapeutics-to-Submit-sNDA-for-FILSPARI-sparsentan-in-FSGS.html